Li Li C C A Bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial A Bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial Blood Blood 2019 2019 134 134 Supplement_1 Supplement_1 930 930 930 930 10.1182/blood-2019-130340 10.1182/blood-2019-130340. This evidence concerns the gene CD38 and plasma cell myeloma.